Hehlmann, R., Lauseker, M., Saussele, S., Pfirrmann, M., Krause, S., Kolb, H.-J., Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Bärlocher, G. M., Heim, D., Fabarius, A., Haferlach, C., Schlegelberger, B., Müller, M. C., Jeromin, S., Prötel, U., Kohlbrenner, K., Burchert, A., Voskanyan, A., Rinaldetti, S., Göbeler, M., Dengler, J., Ho, A., Falge, C., Kanz, L., Kneba, M., Stegelmann, F., Pfreundschuh, M., Waller, C. F., Spiekermann, K., Fuchs, R., Scheid, C., Hänel, M., Köhne, C-H, Brümmendorf, H., Lindemann, H.-W., Berdel, W. E., Staib, P., Balleisen, L., Brossart, P., Schenk, M., Zankovich, R., Geer, T., Hertenstein, B., Bildat, S., Hochhaus, A. and Hasford, J.
(2017):
Assessment of IMATINIB 400mg as first line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV.
In: Hämatologica, Vol. 102: pp. 151-152
Full text not available from 'Open Access LMU'.
Actions (login required)
- View Item
